2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Surgical, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

6169 Specialized cancer care is cost-effective for Medicaid-insured young adults with newly diagnosed acute lymphoblastic leukemia (ALL)

Jerry Luo, MD, MS, Theresa H Keegan, MD, PhD2, Helen Parsons, PhD, MPH3, Katharine Miller, PhD, MPH4, Lori Muffly, MD5, Jeffrey S Hoch, PhD6
1 Stanford University School of Medicine, Palo Alto, California, United States
2 UC Davis Comprehensive Cancer Center, Sacramento, California, United States
3 University of Minnesota, Minneapolis, Minnesota, United States
4 Stanford University School of Medicine, Palo Alto, California, United States
5 Stanford University School of Medicine, Palo Alto, California, United States
6 University of California Davis, Davis, California, United States
Background
Prior studies have demonstrated that adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated at specialized cancer centers (SCC) have superior outcomes. However, fewer than half of young adults receive care at an SCC, and those insured by Medicaid are less likely to be treated at an SCC than commercially insured patients, widening this survival gap. The survival advantage of specialized care must be weighed against higher costs, estimated at approximately twice those of non-SCCs among commercially insured patients (Wolfson et al., Cancer 2021). Whether this survival benefit justifies the added expenditure remains uncertain, particularly for Medicaid-insured AYAs, for whom evidence of value could inform efforts to expand access. To address this question, we conducted a cost-effectiveness analysis of upfront ALL care for young adults at SCCs compared with non-SCCs from a Medicaid perspective.

Methods
Life expectancy estimates were obtained from previous research using state cancer registries from California, New York, and Texas (Muffly et al., JCO Oncology Practice 2021) to calculate annual survival probabilities in a cohort of Medicaid-insured young adults aged 22–39 with ALL diagnosed between 2004 and 2018. Annual expected costs by treatment setting were based on prior research by Wolfson et al., adjusted for assumptions about Medicaid costs relative to commercial payers. We calculated extra effect (ΔE) as the difference in life expectancy between SCC and non-SCC treatment settings over a 5-year time horizon using a 3% discount rate, and we calculated extra cost (ΔC) in a similar fashion. We estimated the incremental cost-effectiveness ratio (ICER) as ΔC/ΔE, the additional cost per additional life-year (LY) gained with treatment at an SCC versus a non-SCC. We tested the robustness of our conclusions by varying key variables in the decision tree used to estimate ΔC and ΔE. For example, we varied the percentage of commercial costs that would potentially be incurred by Medicaid from 0% to 50% and explored the impact of different discount rates (to estimate present value). In addition, we explored a variety of scenario analyses in which a few data inputs were modified to reflect different hypothetical scenarios.

Results
Over the five-year time horizon, the estimated LYs experienced after treatment at SCCs were 3.32 compared with 2.68 at non-SCCs, for an additional 0.64 LYs gained. Under the assumption that Medicaid costs are 20% of commercial costs, the expected costs of treatment at SCCs were $119,733 compared with $51,978 at non-SCCs, for an additional $67,754. The incremental cost for an additional LY (i.e., ICER) based on these estimates is approximately $105,000. Assuming Medicaid costs are 19% or 10% of commercial costs yielded ICER estimates of $100,000 and $50,000, respectively. When Medicaid costs are assumed to be 30% or more of commercial costs, the ICER climbs to over $150,000 per additional LY.

We changed the 3% discount rate to 0% to provide an estimate of undiscounted results. In this scenario, the estimates of incremental effect and incremental cost were 0.70 LYs and $68,497, respectively. The corresponding ICER was approximately $97,855 per additional LY gained. Increasing the discount rate to 5% yielded an ICER estimate of $108,535.

Conclusion
Among Medicaid-insured young adults with ALL, care at an SCC compared with a non-SCC resulted in an ICER of less than $105,000 per life-year gained if the Medicaid reimbursement rate is assumed to be 20% or less of commercial payers’ rates. This ICER falls within common oncology willingness-to-pay thresholds across a range of Medicaid cost assumptions, suggesting that the survival benefits of care at SCCs are achieved at a cost that represents good value for money for public payers. The policy implications appear to be robust to the choice of discount rate over the five-year time horizon of our analysis. Policies that expand access to SCC care for Medicaid-insured AYAs could reduce disparities in outcomes while representing cost-effective investments for public payers.
Jerry Luo, MD, MS: No relevant conflicts of interest to declare.